Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
Batmunkh T, Moore KA, Thomson H, Altangerel B, Amraa O, Avaa N, Batbayar L, Batsukh K, Bright K, Burentogtokh T, Ha Do LA, Dorj G, Hart JD, Javkhlantugs K, Jigjidsuren S, Justice F, Li S, Licciardi PV, Mashbaatar K, Mazarakis N, Neal EFG, Nguyen CD, Ochirbat B, Tsolmon B, Tuya A, Surenjav U, von Mollendorf C, Mulholland K.
Batmunkh T, et al. Among authors: dorj g.
Lancet Reg Health West Pac. 2023 Nov 21;42:100953. doi: 10.1016/j.lanwpc.2023.100953. eCollection 2024 Jan.
Lancet Reg Health West Pac. 2023.
PMID: 38357398
Free PMC article.